News | August 05, 2025
Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
Dr. Muthu was last associated with Mankind Pharma
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
AMP-6 & AMP-8 are special purpose entities formed for purpose of setting up captive solar power projects in Karnataka
Trinity has availed credit facility from Investec for Business for their working capital requirements of Rs. 31.5 crore
The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Inspection included drug device combinations covering our recent filing in nasal sprays domain
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
Subscribe To Our Newsletter & Stay Updated
